Requip, Ropinirole News

New data presented at the 12th International Congress of Parkinson's Disease and Movement Disorders prove that ropinirole is a highly effective molecule in managing Parkinson's disease .

People with restless legs syndrome are sometimes prescribed Parkinson's disease drugs to treat what they describe as an irresistible urge to move their legs, especially at night.

FDA APPROVES REQUIP XL , THE FIRST AND ONLY ORAL ONCE-DAILY NON-ERGOT DOPAMINE AGONIST FOR PARKINSON'S DISEASE Extended-Release Formulation Improved Symptoms in Patients Not Optimally Controlled with Levodopa ...

Requip XL is the first and only oral once-daily non-ergot dopamine agonist indicated for Parkinson's disease.

Topical thrombin is available to help stop oozing and minor bleeding. Intravascular administration can have devastating consequences.

How generic Requip may lead to the extinction of restless legs syndrome : Last week, the drug agency approved the first generic versions of ropinirole tablets for four manufacturers.

GSK Launches ReQuip XL A New Once Daily Formulation For The Treatment Of Parkinson's Disease Main Category: Parkinson's Disease Article Date: 19 May 2008 - 1:00 PDT GlaxoSmithKline have announced the launch of ... via Medical News Today

"After a speedy rise as one of the nation's oddest-sounding designer disorders, restless legs syndrome may have run its course. via ISIL Channels

The FDA has approved generic versions of the drug Requip made by four companies. via WebMD Health News Center

“Although we are forecasting a total of 12 named storms in 2008, A... a relatively high percentage of tropical storms are expected to make landfall and the major threat area is farther north than normal”

A U.S. meteorological service is predicting a near average number of hurricanes this year but with an increased risk of storms along the U.S. East Coast. via Political Gateway

“One of the things that we found that we can't fully explain is that they have more robust effects early in therapy”

The drugs that are widely used to treat restless legs syndrome do provide relief, but they are burdened by side effects and a gradual loss of effectiveness that causes many sufferers to stop taking them, a new ... via Health Scout

A dopamine agonist used to treat restless legs syndrome - Requip - has been approved in generic form, the FDA announced on Friday. via Journal Watch - Medicine that Matters

“This generic drug approval is an example of the FDA's efforts to increase access to safe and effective generic drugs as soon as the law permits”

The U.S. Food and Drug Administration has approved the first generic versions of Requip tablets for the treatment of moderate to severe Restless Legs Syndrome. via Food and Drug Administration

COLUMBUS, Ohio, May 5 /PRNewswire/ -- Roxane Laboratories, Inc. announced today the approval of its Abbreviated New Drug Application for Ropinirole Hydrochloride Tablets, 0.25mg, 0.5mg, 1mg, 2mg, 3mg, 4mg, 5mg ... via Earth Times

Antares Pharma, Inc. announced that its partner, Jazz Pharmaceuticals, Inc. plans to initiate a Phase III clinical trial for a Central Nervous System product candidate they call JZP-7 which utilizes Antares ' ... via Earth Times

SkyePharma PLC has been informed that the United States Food and Drug Administration has extended the Prescription Drug User Fee Act action date for GlaxoSmithKline's Requip XLTM Extended Release tablets. via BioSpace

“When your legs feel better, you feel better.”

The television advertisements for Mirapex show a stick figure, whose legs have annoying sensations that keep it up at night-sensations like "lightning legs," "pins and needles," "creepy crawlies," and "the urge ... via Trial

Q. A 73-year-old woman is evaluated by her family practice physician for syncope. via RNweb

Friday's news that the Israeli generic drug maker Teva Pharmaceutical Industries Ltd. via Blogging Stocks

Nov 30, 2007 - Teva Pharmaceutical Industries Ltd. announced today that the U.S. Food and Drug Administration has granted tentative approval for the Company's Abbreviated New Drug Application to market its ... via Med Ad News